INFARMED hosted this week the eighth meeting under the scope of the Portuguese Presidency of the Council of the European Union. The event gathered over 70 participants of the Committee on Herbal Medicinal Products (HMPC).
During the two days of the meeting the debate focused on the medicinal use of cannabis and Herbal Medicinal Products on COVID-19 prevention and treatment. Besides presiding over the meeting, INFARMED was also responsible for sharing its experience regarding cannabis, namely the international, European and national regulatory framework. The INFARMED experts also presented their perspectives on the implementation of legislation related to the use of medicines and preparations made from cannabis in all phases of the circulation.
On the second day of the meeting, the focus was on the potential use of Herbal Medicinal Products for COVID-19 prevention and treatment. It was noted the need for further studies in order to address issues such as the implications, side effects and positive outcome.
It was also emphasized the importance of credible information regarding the possibility of interactions between Herbal Medicinal Products and other medicines, for doctors and patients alike. The take on this issue was provided by the Observatory of Herb-Drug Interactions (OIPM), of Coimbra’s University Faculty of Pharmacy.
The Committee on Herbal Medicinal Products is the European Medicines Agency's (EMA) committee responsible for compiling and assessing scientific data on herbal substances, preparations and combinations, to support the harmonization of the European market. The Committee was established in accordance with Regulation (EC) No 726/2004 and the Herbal Directive, which introduced a simplified registration procedure for traditional herbal medicinal products in EU Member States.
The meeting is part of the set of 20 meetings of the several Committees and Working Groups that INFARMED will be holding during the next months of the Presidency.